Filtered By:
Drug: Avastin

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 69 results found since Jan 2013.

Intravenous Thrombolysis for Ischemic Stroke in Recurrent Oligodendroglioma: A Case Report
We present the case of successful IV thrombolysis with rtPA for AIS in a patient with oligodendroglioma on bevacizumab without hemorrhagic complications. We summarize the published cases of thrombolysis in AIS in patients with intracranial neoplasms.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Rima M. Dafer, Nina Paleologos, Deborah Lynch Tags: Case Reports Source Type: research

Value of Eye Movement Exam in Aiding Precise Localization in Stroke (P1.016)
We present an unusual presentation of midbrain stroke presenting with bilateral ptosis in an African American male with vascular risk factors and concurrent use of bevacizumab. This case illustrates how detailed knowledge of anatomy and detailed neurologic exam remain valuable tools for localizing and diagnosing subtle presentations of common neurologic disease. Case description: A 69 year-old African American man with vascular risk factors including hypertension, hyperlipidemia and poorly controlled diabetes experienced sudden onset horizontal diplopia associated with fatigue. The patient presented to the Emergency Depart...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Khandker, N., Schmerler, D., Mahajan, S., Serra, A., Strbian, D. Tags: Cerebrovascular Disease and Interventional Neurology I ePosters Source Type: research

Pyruvate kinase M2 (PKM2) improve symptoms of post ‐ischemic stroke depression by activating VEGF to mediate the MAPK/ERK pathway
ConclusionPKM2 improves symptoms of post-ischemic stroke depression by activating VEGF-mediated MAPK/ERK pathway.
Source: Brain and Behavior - December 13, 2021 Category: Neurology Authors: Yun Feng, Xuebin Li, Jie Wang, Xiaohua Huang, Lanqing Meng, Jianmin Huang Tags: ORIGINAL ARTICLE Source Type: research

Ischemic stroke in a patient with EGFR ‐mutated non–small‐cell lung cancer after treatment with ramucirumab
This article presents the case of a non–small-cell lun g cancer patient who experienced a new ischemic stroke after treatment with ramucirumab. The findings suggest that further studies may be necessary to investigate the relationship between ramucirumab and the risk of ischemic stroke.
Source: Thoracic Cancer - October 29, 2022 Category: Cancer & Oncology Authors: Guo ‐Yu Chen, Wen‐Chien Cheng, Chih‐Yen Tu Tags: CASE REPORT Source Type: research

Ischemic stroke in patients with gliomas at The University of Texas-M.D. Anderson Cancer Center
Abstract Patients with gliomas are at risk of cerebrovascular accidents (CVA) with potential consequences on survival, function, and local tumor control. Our objective was to provide information about CVA in patients with gliomas and to estimate survival in this group. We reviewed all adult glioma patients with ischemic CVA at the University of Texas-M.D. Anderson Cancer Center from 2003 through 2014. We extracted demographic, clinical, imaging, treatment and outcome data. We used descriptive summary data and estimated or compared survival rates where appropriate. 60 of 6500 patients (0.1 %) with high-grade (HGG,...
Source: Journal of Neuro-Oncology - August 14, 2015 Category: Cancer & Oncology Source Type: research

Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration
In their article “Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration,” Etminan and associates perform a retrospective study and a nested case-control study in order to examine the risk of myocardial infarction (MI) and stroke associated with bevacizumab intravitreal injections for neovascular age-related macular degeneration (AMD).1
Source: American Journal of Ophthalmology - April 10, 2016 Category: Opthalmology Authors: Joel Hanhart, Shlomo Vinker Tags: Correspondence Source Type: research

Risk of Myocardial Infarction and Stroke with Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration
To examine the risk of myocardial infarction and stroke with single and repeated doses of intravitreal bevacizumab in wet age related macular degeneration (AMD).
Source: American Journal of Ophthalmology - December 14, 2015 Category: Opthalmology Authors: Mahyar Etminan, David A. Maberley, David W. Babiuk, Bruce C. Carleton Tags: Original Articles Source Type: research

Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab
AbstractBevacizumab (BVZ), a monoclonal antibody directed against vascular endothelial growth factor (VEGF), has been suspected to increase the incidence of ischemic stroke (IS) and intracranial hemorrhage (ICH) in GBM patients. Intracranial vascular events, such as IS and ICH, were retrospectively analyzed in 364 MRI scans of 82 patients with recurrent GBM (1st/2nd/3rd relapse). Out of these 82 patients, 40 were treated with BVZ (178 scans) in addition to basic treatment, whereas 42 patients matching for age and gender received basic treatment (186 scans). Distribution of typical vascular risk factors between both groups ...
Source: Journal of Neuro-Oncology - May 29, 2017 Category: Cancer & Oncology Source Type: research

Bilateral central retinal vein occlusions in a young patient with a history of eosinophilic pneumonia and thalamic stroke
Conclusion: Central retinal vein occlusion in young patients is a rare condition often presenting as a manifestation of an underlying inflammatory or hematological disorder. Combined anti–vascular endothelial growth factor treatment and pan-retinal photocoagulation may have resolved the associated cystoid macular edema in this case, although continued observation is necessary.
Source: Retinal Cases and Brief Reports - October 1, 2018 Category: Opthalmology Tags: Case Report Source Type: research

Cn-14 * retrospective analysis of ischemic cerebral strokes in patients diagnosed with a glioblastoma during the course of a bevacizumab treatment
Bevacizumab is an anti-vascular endothelial growth factor approved in the treatment of recurrent glioblastoma. It prolongs progression-free survival, improes radiologic response and contributes to reduce the dose of dexamethasone required to control peritumoral edema. Arterial and venous thromboembolic events represent significant toxicities related to the use of angiogenesis inhibitors. Various mechanisms could be implicated in bevacizumab-related strokes, as cardioembolic, lacunar stroke related to hypertension, deep venous thrombosis passing through a patent foramen ovale, pro-coagulant effect of the underlying glioblas...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Maurice, C., Mason, W. P. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

Cn-20 * bevacizumab causing recurrent cerebral infarction in a patient with glioblastoma: a previously undocumented phenomenon
CONCLUSIONS: Here we describe a case of an ischemic stroke with radiographic correlate while on bevacizumab, with clinical improvement arrested by the development of a recurrent stroke when bevacizumab was restarted. Interestingly, the distal arteries within the stroke bed appeared somewhat attentuated, suggestive of radiation vasculopathy. This case, describing a previously undocumented phenomenon, raises the possibility of a synergistic effect of bevacizumab and radiation vasculopathy. It may be that radiation vasculoapthy alone is typically insufficient to cause ischemia, but the addition of bevacizumab may precipitate ...
Source: Neuro-Oncology - November 3, 2014 Category: Cancer & Oncology Authors: Winkel, D., Voloschin, A. Tags: COMPLICATIONS OF THERAPY AND NEUROTOXICITY Source Type: research

Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events.
CONCLUSION:: In our study population, patients treated with intravitreal bevacizumab were significantly more likely to experience stroke during 2 years after first injection. PMID: 30618282 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - January 8, 2019 Category: Opthalmology Authors: Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J Tags: Eur J Ophthalmol Source Type: research

Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies
Conclusion Published data on IVTB in AMRD provide only a low level of evidence on its cardiovascular safety and do not support any finite conclusions.
Source: Drug Safety - March 7, 2016 Category: Drugs & Pharmacology Source Type: research

Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration
Purpose of review: The purpose of review is to summarize the literature addressing nonocular adverse events in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor (VEGF) inhibitors and to present possible mechanisms of effect. Recent findings: The incidence of overall nonocular serious adverse events varied from 0 to 39.3% and nonocular adverse events ranged from 0 to 86.9%. Few studies have reported a significant association between use of intravitreal anti-VEGF agents and overall incidence of adverse events, stroke, myocardial infarction, nonocular hemo...
Source: Current Opinion in Ophthalmology - April 8, 2016 Category: Opthalmology Tags: RETINAL, VITREOUS AND MACULAR DISORDERS: Edited by Brandon G. Busbee and John W. Kitchens Source Type: research